AbbVie (ABBV) Selling, General & Administrative (2012 - 2026)
AbbVie (ABBV) Selling, General & Administrative (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 6.43 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.63 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.90 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 5.65 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.75 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.92 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 3.41 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2.95 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.63 Bn |
| Mar 31, 2026 | 3.58 Bn |
| Dec 31, 2025 | 3.90 Bn |
| Sep 30, 2025 | 3.57 Bn |
| Jun 30, 2025 | 3.25 Bn |
| Mar 31, 2025 | 3.29 Bn |
| Dec 31, 2024 | 3.86 Bn |
| Sep 30, 2024 | 4.21 Bn |
| Jun 30, 2024 | 3.38 Bn |
| Mar 31, 2024 | 3.32 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Sep 30, 2023 | 3.37 Bn |
| Jun 30, 2023 | 3.27 Bn |
| Mar 31, 2023 | 3.04 Bn |
| Dec 31, 2022 | 3.42 Bn |
| Sep 30, 2022 | 3.30 Bn |
| Jun 30, 2022 | 5.41 Bn |
| Mar 31, 2022 | 3.13 Bn |
| Dec 31, 2021 | 3.26 Bn |
| Sep 30, 2021 | 3.08 Bn |